Citations

Clear

22 citation(s) found for "Menser, T".

Assessing Alignment of Referrals with Guidelines for the Treatment of Children with Obesity
Borkar, Shalmali R. , Kumar, Seema, Biggs, Bridget K , Standen, Erin C, Biggs, Bridget K. , Standen, Erin C. , Menser, Terri

Mayo Clinic

Childhood Obesity | September 30, 2025 | Volume: 21 | Issue: 8 | Pages: 682-687

10.1177/21532176251370126 | PMID 40833824 Get It

It is unknown how many children with obesity are offered treatments aligned with clinical practice guidelines. This study examined electronic medical record data from a Midwest, USA, health system to quantify referrals to obesity treatment among patients 2–17 years old with obesity presenting for well-child visits in 2022 and/or 2023. Mixed-effects logistic regression models tested associations of referral placement with child characteristics, the Area Deprivation Index, and distance to specialty care. Of 14,893 patients, 591 (4.0%) received a referral. Referrals were associated with severe obesity ( p < 0.001), older age ( p < 0.001), proximity to specialty care ( p < 0.001), number of well-visits ( p ≤ 0.001), and identification with a minoritized race or ethnicity ( p < 0.05–0.001). Findings indicate a large gap from the current state of referrals to alignment with practice guidelines for pediatric obesity. Furthermore, research needs to explore and address barriers to referrals and treatment access.
1631: ASSOCIATION OF INDUCTION AGENTS FOR INTUBATION AND OUTCOMES IN SEPSIS: A TARGET TRIAL EMULATION
Bhavsar, Vatsa, Khanijo, Aditya , Anes, Joguncic, KC, Anil, Rodriguez, Allison Perez, FRÍAS, JORGE SINCLAIR DE , Cureton, Kimberly D., Robbins, Kellie, Reddy, Swetha , Lal, Amos , Kashani, Kianoush , Franco, Pablo Moreno , Ghosh, Saptarshi , Menser, Terri

Mayo Clinic

Critical Care Medicine | January 31, 2025 | Volume: 53 | Issue: 1 | Pages: No page available

10.1097/01.ccm.0001105188.86464.c3 Get It

Cumulative deficits frailty index and relationship status predict survival in multiple myeloma
Abdallah, Nadine , Dizona, Paul, LaPlant, Betsy, Schaeferle, Gavin, Aug, Sarah, Weivoda, Megan , Buadi, Francis K. , Warsame, Rahma , Lacy, Martha Q. , Hayman, Suzanne R. , Kumar, Shaji , Menser, Terri , Weivoda, Megan , Dispenzieri, Angela , Buadi, Francis K , Warsame, Rahma , Cook, Joselle M , Lacy, Martha Q , Gertz, Morie A , Kumar, Shaji K , Kumar, Amanika , Dispenzieri, Angela , Cook, Joselle , Gertz, Morie A. , Rajkumar, S. Vincent

Mayo Clinic

Blood Advances | December 18, 2024 | Volume: 9 | Issue: 5 | Pages: 1137-1146

10.1182/bloodadvances.2024014624 | PMID 39693516 Get It

Abstract Several tools have been proposed for assessing frailty in multiple myeloma (MM), but most are based on clinical trial data sets. There are also limited data on the association between frailty and patient-reported outcomes and on the prognostic value of social determinants of health. This study evaluates the prognostic impact of frailty, based on the cumulative deficit frailty index (FI), and relationship and socioeconomic status (SES) in patients with newly diagnosed MM. This retrospective study included 515 patients with MM seen at Mayo Clinic (Rochester, MN) at diagnosis between 2005 and 2018. The FI was calculated using patient-reported data on activities of daily living and comorbidity data, with items scored as 0, 0.5, or 1, in which 1 indicated a deficit. The FI was calculated by dividing the total score by the number of nonmissing items. Frailty was defined as FI ≥0.15; 61% were nonfrail, and 39% were frail. Frailty and nonmarried/relationship status were associated with higher disease stage, decreased the likelihood of early transplantation, and independently associated with decreased survival. SES was not independently associated with survival. Frail patients reported worse scores for fatigue, pain, and quality of life. Approximately a quarter of patients had a deterioration in frailty status at 3 to 12 months, and &lt;10% had improvement. In conclusion, a cumulative deficit FI was associated with higher symptom burden and decreased survival in a real-world cohort of patients with newly diagnosed MM. Frailty status is dynamic and should be reassessed during treatment. Social support has prognostic value and should be evaluated in clinical practice.
Frailty-Based Outcomes with Bispecific Antibodies in Older Patients with Multiple Myeloma
Abdallah, Nadine , Gupta, Supriya , Elhaj, Mohammed, Bansal, Radhika , Schaeferle, Gavin, Kourelis, Taxiarchis , Warsame, Rahma , Kapoor, Prashant , Hayman, Suzanne R. , Gertz, Morie A., Lin, Yi, Kumar, Shaji, Rees, Matthew J. , Menser, Terri , Cook, Joselle , Gonsalves, Wilson I. , Buadi, Francis K. , Dingli, David , Gertz, Morie A. , Kumar, Shaji

Mayo Clinic

Blood | December 5, 2024 | Volume: 144 | Issue: Supplement 1 | Pages: 4695-4695

10.1182/blood-2024-211768 Get It

Background: Multiple Myeloma (MM) is predominantly a disease of older adults. However, older patients vary widely in physiological status and treatment tolerance. The simplified frailty index (Facon 2020) incorporates age, ECOG performance status, and comorbidities (Charleston Comorbidity Index [CCI]) to classify patients as frail or non-frail. While frailty is associated with increased toxicity with conventional systemic therapies, its impact on outcomes of older patients treated with bispecific antibodies (BsAbs) has not been established. Thus, we conducted a retrospective study to evaluate the efficacy and toxicity of BsAbs in older patients based on frailty. Methods: This is a single institution study. We included patients with MM ≥65 years who initiated treatment with a BsAb at Mayo Clinic in Rochester, MN from August, 2018 to January, 2024. Patients who received a BsAb on trial or as standard of care were included. For patients who received 2 different BsAbs at different timepoints, we included the first treatment only. We grouped patients into frail and non-frail based on the simplified frailty index (score ≥2 = frail). We evaluated the overall response (ORR) and ≥very good partial response (VGPR) rates, progression-free (PFS) and overall (OS) survival, early mortality (within 90 days) including early non-relapse mortality (NRM), and toxicities including cytokine release syndrome (CRS), immune effector cell associated neurotoxicity syndrome (ICANS) and healthcare utilization. P values were insignificant (&gt;0.05) unless otherwise stated. PFS and OS were calculated from the day of BsAb start. Results: A total of 99 patients age 65-89 years were included. The products used were teclistamab (N=43), talquetamab (N=2), and investigational agents (N=54); 67% were ≥70 and 29% were ≥75 years; 39% were female, 95% were non-Hispanic White and 4% were Black/African American. Seventy patients (71%) were considered frail and 29 (29%) were non-frail. At the time of BsAb start, a higher proportion of frail patients had platelets &lt;75 x 10^9/L (30% vs 8%, P=0.04). Otherwise, there was no significant difference between frail and non-frail patients in age (median: 72 vs 70), hemoglobin &lt;8 g/dL (19% vs 12%), absolute neutrophil count &lt;1 x 10^9/L (6% vs 8%), presence of high-risk FISH (70% vs 60%), ISS stage 3 (32% vs 41%), high LDH (58% vs 61%), presence of extramedullary disease (39% vs 25%), serum creatinine ≥2 mg/dL (15% vs 8%), bone marrow plasma cell% (20% in both), triple- (83% vs 90%) and penta-class refractoriness (63% vs 48%), number of prior lines of therapy (median: 6 in both), prior exposure to BCMA-directed therapy (24% vs 21%, P=0.80) and prior autologous stem cell transplant (73% vs 86%). Step-up dosing was used in 81% vs 48% of patients (P=0.001), and treatment was initiated in the outpatient setting in 46% vs 28% (P=0.12) in frail and non-frail patients, respectively. The median follow-up was 1.9 (95%CI: 1.0-2.3) years. There was no significant difference between frail and non-frail patients in ORR (52% vs 62%), ≥VGPR (46% vs 48%), 1-year PFS (36% vs 48%, P=0.26), or 1-year OS (57% vs 61%, P=0.30), respectively. Age and CCI alone were not associated with PFS or OS, but ECOG &gt;1 was associated with decreased PFS (hazard ratio: 3.1, P=0.001) and OS (hazard ratio: 3.1, P&lt;0.001). There was no significant difference between frail vs non-frail patients in grade 3/4 thrombocytopenia (39% vs 17%, P=0.06), grade 3/4 neutropenia (27% vs 35%), total days of hospitalization (median: 8 vs 5, P=0.35), number of unplanned admissions in 6 months (median: 1 in both), or total hospital days for unplanned admissions (1 vs 2 days). There was no significant difference between frail and non-frail patients in early mortality (23% vs 10%, P=0.17), including early NRM (4% in both), CRS (59% vs 66%), grade 3-4 CRS (3% vs 7%), or CRS recurrence (21% vs 10%). ICANS occurred in 5 (9%) frail patients and 1 non-frail patient (grade 2); among frail patients, grades were: 1 in 3 patients, 3 in 1 patient, and 4 in 1 patient. Similarly, there was no significant difference in CRS/ICANS between the 2 groups when patients with and without step-up dosing were analyzed separately. Conclusion: Frailty, defined using the simplified frailty index, was not significantly associated with inferior efficacy or increased toxicity with BsAb therapy among older patients with MM. Poor performance status predicted inferior PFS and OS, while age and comorbidity scores did not.
Prognostic impact of patient-reported symptoms in multiple myeloma
Abdallah, Nadine , Bohra, Arwa , Mammadzadeh, Aytaj , Buadi, Francis K. , Kapoor, Prashant , Gertz, Morie A. , Hayman, Suzanne R. , Elhaj, Mohammed, Dingli, David , Binder, Moritz , Lin, Yi , Kourelis, Taxiarchis , Warsame, Rahma , Thompson, Carrie A. , Kumar, Shaji , Buadi, Francis K , Dispenzieri, Angela , Gertz, Morie A , Cook, Joselle M , Binder, Moritz , Kourelis, Taxiarchis , Warsame, Rahma , Thompson, Carrie, Menser, Terri , Kumar, Shaji K , Dingli, David , Dispenzieri, Angela , Cook, Joselle , Rajkumar, S. Vincent

Mayo Clinic

Blood Advances | December 5, 2024 | Volume: 9 | Issue: 4 | Pages: 884-892

10.1182/bloodadvances.2024014232 | PMID 39637309 Get It

Abstract Patient-reported outcomes (PROs) are associated with treatment outcomes in multiple myeloma (MM) in the clinical trial setting. However, most PRO tools are time consuming, which hinders use in routine practice. Our institution incorporated a “Hematology Patient-Reported Symptom Screen” (HPRSS), a 3-item questionnaire for fatigue, pain, and quality of life (QOL). The main objective of this study was to evaluate the impact of these symptoms on progression-free survival (PFS) and overall survival (OS) in a real-world cohort of patients with newly diagnosed MM. This retrospective study included patients with MM diagnosed between April 2011 and December 2017, seen at Mayo Clinic (Rochester, MN), who completed the HPRSS. Patients rated their symptoms on a scale from 0 to 10. Clinically relevant symptoms were defined as scores ≥5 for pain and fatigue, and ≤5 for QOL. At diagnosis, 735 patients had scores for all domains. The median follow-up was 8.1 years. Age was associated with increased odds of fatigue and decreased QOL. Female sex and comorbidities were associated with fatigue and pain. Higher disease stage, anemia, lytic lesions, and increased plasma cell burden were associated with fatigue, pain, and decreased QOL. Clinically relevant fatigue, pain, and decreased QOL were associated with decreased PFS and OS. On multivariate analysis including age, International Staging System III, high-risk cytogenetics, and postinduction transplantation, fatigue and decreased QOL were independently associated with decreased OS. A composite HPRSS score stratified patients into 3 groups with distinct OS. Patient-reported symptoms are prognostic in patients with newly diagnosed MM. The prognostic values of fatigue and decreased QOL are independent of age, disease stage, and transplant status.
Evaluating adoption and reach in a pragmatic randomized trial of community paramedicine for intermediate acuity patient care
Ridgeway, Jennifer L. , Sundt, Wendy J., Krpata, Tami, Glasgow, Amy E. , Smith-Stellflug, Jamie L, Juntunen, Michael B. , Liedl, Chad P., Hentz, Joseph G. , McCoy, Jessica, Sundt, Wendy J S, Krpata, Tami S, Glasgow, Amy, Smith, Olivia A, Lampman, Michelle A. , Menser, Terri L, McCoy, Jessica J, Ridgeway, Jennifer L , Smith, Jamie L , Smith, Olivia A., Menser, Terri , McCoy, Rozalina G.

Mayo Clinic

Journal of Clinical and Translational Science | October 17, 2024 | Volume: 8 | Issue: 1 | Pages: No page available

10.1017/cts.2024.646 | PMID 39655042 Get It

Abstract Introduction: Pragmatic trials aim to speed translation to practice by integrating study procedures in routine care settings. This study evaluated implementation outcomes related to clinician and patient recruitment and participation in a trial of community paramedicine (CP) and presents successes and challenges of maintaining pragmatic study features. Methods: Adults in the pre-hospital setting, emergency department (ED), or hospital being considered for referral to the ED/hospital or continued hospitalization for intermediate-level care were randomized 1:1 to CP care or usual care. Referral and enrollment data were tracked administratively, and patient characteristics were abstracted from the electronic health record (EHR). Enrolled patients completed baseline surveys, and a subset of intervention patients were interviewed. All CPs and a sample of clinicians and administrators were invited to complete a survey and interview. Results: Between January 2022 and February 2023, 240 enrolled patients (42% rural) completed surveys, and 22 completed an interview; 63 staff completed surveys and 20 completed an interview. Ninety-three clinicians in 27 departments made at least one referral. Factors related to referrals included program awareness and understanding the CP practice scope. Most patients were enrolled in the hospital, but characteristics were similar to the primary care population and included older and medically complex patients. Challenges to achieving representativeness included limited EHR infrastructure, constraints related to patient consenting, and clinician concerns about patient randomization disrupting preferred care. Conclusion: Future pragmatic trials in busy clinical settings may benefit from regulatory policies and EHR capabilities that allow for real-world study conduct and representative participation. Trial registration: NCT05232799.
Rethinking Measures and Mortality Attribution in Health Care: The ENT Example
Patel, Samip , Olivero, Lorenzo , FRÍAS, JORGE SINCLAIR DE , Anderson, Stephanie S., Pollock, Ben D., Lee, Marian D., Chirilă, Răzvan M. , Guru, Pramod , Pollock, Benjamin D. , Sinclair, Jorge Enrique , Guru, Pramod K , Taylor, Richard, Moreno Franco, Pablo , Patel, Samip N , Pollock, Benjamin D , Lee, Marian D., Murthy, Hemant S. , Taylor, Richard A. , Franco, Pablo Moreno , Menser, Terri

Mayo Clinic

Otolaryngology–Head and Neck Surgery | October 13, 2024 | Volume: 171 | Issue: 6 | Pages: 1925-1927

10.1002/ohn.1015 | PMID 39396155 Get It

AbstractNational performance metrics ultimately enhance patient decision‐making and promote meaningful improvements in health care delivery, which makes having valid and reliable measures essential. This study examined US News and World Report metrics from 2019 to 2012 and used electronic health record data, combined with detailed chart review across 3 in‐system hospitals, to assess the provision of care compared to the attribution of patients assigned to the ear, nose, and throat (ENT) mortality group. Of the initial 47 ENT‐attributed deaths, 23 of those were verified, dimensioning the mortality rate from 1.7% to just 0.8%. These results underscore the necessity of rethinking measures and mortality attribution methodologies to be more accurate. Current methods use Medicare Severity Diagnosis Related Group billing coding to map the attribution. We suggest transitioning away from specialty ranking approaches and towards a procedure and condition “rating” approach to ensure that these ranking types capture data about the provision of care within a given encounter.
Frailty predicts adverse outcomes in older patients with pulmonary embolism
FRÍAS, JORGE SINCLAIR DE , Olivero, Lorenzo , GABELA, ABIGAIL, Jaen, Diana, Franco, Pablo Moreno , Sinclair, Jorge Enrique , Moreno Franco, Pablo , Menser, Terri

Mayo Clinic

Geriatrics & Gerontology International | August 15, 2024 | Volume: 24 | Issue: 9 | Pages: 924-929

10.1111/ggi.14961 | PMID 39143935 Get It

Aim This study aims to evaluate the impact of frailty on the outcomes of older patients with pulmonary embolism (PE). Methods Using the National Inpatient Sample database, we identified 288 070 patients aged 65 or older who were admitted with a primary diagnosis of PE from 2017 to 2019. Frailty was assessed using the Hospital Frailty Risk Score (HFRS), and patients were categorized into low‐, intermediate‐, and high‐frailty‐risk groups. Multivariate logistic regression was used to calculate adjusted odds ratios for all outcomes. Results These patients were categorized into low‐risk (57.6%, 161 420), medium‐risk (39.9%, 111 805), and high‐risk (2.5%, 7075) groups. High‐risk patients, predominantly females with multiple comorbidities, exhibited significantly higher mortality rates and adverse outcomes. The HFRS showed a good discriminating ability in predicting mortality (area under the receiver operating characteristic curve = 0.7796). Frailty was associated with increased use of advanced therapeutic interventions and critical care resources such as thrombolysis, catheter‐directed therapies, inferior vena cava filter placement, mechanical ventilation, vasopressor use, and intensive care unit admission. Conclusion Frailty markedly affects outcomes in older PE patients. The HFRS offers a valuable prognostic tool in this population, suggesting that integrating frailty assessments into clinical practice could enhance care strategies and improve patient outcomes. Our findings underscore the need for further research to refine frailty‐based care paradigms. Geriatr Gerontol Int 2024; 24: 924–929 .
Health equity engineering: Optimizing hope for a new generation of healthcare
Enders, Felicity , Brooks, Tayla R., Carr, Allison R. , Cullen, John P. , DiazGranados, Deborah , Gaba, Ayorkor , Johnson, Leigh , Messinger, Shari , Milam, Adam J. , Perkins, Susan M. , Pineda, Tiffany Danielle , Periyakoil, Vyjeyanthi S. , Hanlon, Alexandra L. , Enders, Felicity T , Golembiewski, Elizabeth H , Cullen, John P , DiazGranados, Deborah , Gaba, Ayorkor , Orellana, Minerva A , Pineda, Tiffany D Chisholm , Milam, Adam J , Messinger, Shari , Golembiewski, Elizabeth H. , Balls‐Berry, Joyce E. , Brooks, Tayla Rashanaye , Menser, Terri , Orellana, Minerva , Thurston, Sally W.

Mayo Clinic

Journal of Clinical and Translational Science | May 22, 2024 | Volume: 8 | Issue: 1 | Pages: No page available

10.1017/cts.2024.549 | PMID 39478773 Get It

Abstract Medical researchers are increasingly prioritizing the inclusion of underserved communities in clinical studies. However, mere inclusion is not enough. People from underserved communities frequently experience chronic stress that may lead to accelerated biological aging and early morbidity and mortality. It is our hope and intent that the medical community come together to engineer improved health outcomes for vulnerable populations. Here, we introduce Health Equity Engineering (HEE), a comprehensive scientific framework to guide research on the development of tools to identify individuals at risk of poor health outcomes due to chronic stress, the integration of these tools within existing healthcare system infrastructures, and a robust assessment of their effectiveness and sustainability. HEE is anchored in the premise that strategic intervention at the individual level, tailored to the needs of the most at-risk people, can pave the way for achieving equitable health standards at a broader population level. HEE provides a scientific framework guiding health equity research to equip the medical community with a robust set of tools to enhance health equity for current and future generations.
Cumulative Deficits Frailty Index and Relationship Status Predict Survival in Multiple Myeloma
Kumar, Shaji , Abdallah, Nadine , Dizona, Paul, LaPlant, Betsy, Terri, Menser, Aug, Sarah, Weivoda, Megan , Buadi, Francis K. , Warsame, Rahma , Lacy, Martha Q. , Hayman, Suzanne R. , Buadi, Francis K , Kumar, Amanika , Dispenzieri, Angela , Cook, Joselle , Gertz, Morie A. , Rajkumar, S. Vincent

Mayo Clinic

No container title available | May 15, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-4373874/v1 Get It

AbstractSeveral tools exist for assessing frailty in multiple myeloma (MM), but most are based on clinical trial datasets. In this study, we evaluate the prognostic impact of frailty based on the cumulative deficit frailty index (FI), and the prognostic impact of relationship and socioeconomic status (SES) in newly diagnosed MM patients. This is a retrospective study including 515 patients with MM seen at Mayo Clinic (Rochester, MN) at diagnosis between 2005–2018. The FI was calculated using patient-reported data on activities of daily living and comorbidity data. Items were scored as 0/0.5/1, with 1 indicating deficit. The FI was calculated by adding individual scores and dividing that by the number of non-missing items. Frailty was defined as FI ≥ 0.15; 61% were non-frail and 39% were frail. Frailty and non-married/relationship status were associated with higher disease stage, decreased likelihood of early transplantation, and independently associated with decreased survival. SES was not independently associated with survival. Frail patients reported worse scores for fatigue, pain, and quality of life. In conclusion, a cumulative deficit FI was associated with higher symptom burden and decreased survival in a real-world cohort of newly diagnosed MM patients. Social support has prognostic value and should be assessed in clinical practice.